ACOR News and Press, Acorda Therapeutics Inc. From 03/04/21

Acorda Therapeutics (ACOR) shares were choppy during after market trading as the company posted fourth-quarter revenue that beat Wall Street estimates and talked up its financial position, buoyed by the recent sale of its manufacturing operations in Chelsea and its restructuring measures.The ...

Acorda Therapeutics (ACOR): Q4 Non-GAAP EPS of -$2.50 misses by $1.02; GAAP EPS of -$9.82 misses by $7.25.Revenue of $38.16M (-24.4% Y/Y) beats by $4.16M.Press Release For further details see: Acorda Therapeutics EPS misses by $1.02, beats on revenue

Sale of Manufacturing Operations to Catalent with net proceeds of ~$74 million Annual operating expenses cut by ~$40 million via sale, restructuring, and other reductions Total 2021 non-GAAP operating expense expected to be $130-$140 million 1 AMPYRA ® (dalfam...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter and year end 2020 update and financial results on Thursday, March 4 at 4:30 p.m. ET. To participate in the Webcast/Conference Call, please note there is a new pre-...

Often, the action in a stock is based on investors perceptions, but it can be a circular event.  Not only is the price action representative of perception, but it can influence perception too.  In the case of Acorda Therapeutics (NASDAQ: ACOR) we can see this in the charts.&#x...

Acorda Therapeutics (ACOR) announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is resigning effective mid-March, 2021. Mr. Lawrence will take a leadership position at an early-stage biotechnology company.Robert Morales, ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is resigning from the Company effective mid-March, 2021. Mr. Lawrence will take a leadership position at an early-stage biotechnol...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the sale of its manufacturing operations in Chelsea, Massachusetts to Catalent. Under the terms of the agreement, Catalent has paid Acorda $80 million in cash, resulting in expected net proceeds to Acorda of ...

Gainers: Live Ventures (LIVE) +87%.GameStop (GME) +63%.Exela Technologies (XELA) +51%.AMMO (POWW) +41%.Castor Maritime (CTRM) +35%.Acorda Therapeutics (ACOR) +32%.Root (ROOT) +32%.Ondas Holdings (ONDS) +30%.NuCana (NCNA) +26%.Foresight Autonomous (FRSX) +26%.Losers:&#...

Gainers: Acorda Therapeutics (ACOR) +45%, NuCana (NCNA) +26%, Synlogic (SYBX) +24%, Evoke Pharma (EVOK) +23%, Tiziana Life Sciences (TLSA) +14%.Losers: Zomedica (ZOM) -26%, Forward Pharma (FWP) -15%, Provention Bio (PRVB) -14%, Acutu...